NeoGenomics Announces \$275 Million Convertible Senior Notes Offering: Key Details for Investors
Fort Myers, FL, June 5, 2026 — NeoGenomics, Inc. (NASDAQ: NEO), a premier provider of oncology diagnostic solutions, has announced a proposed private offering of \$275 million in aggregate principal amount of convertible senior notes due 2032. This strategic move is designed to bolster the company’s capital structure and may have significant implications for existing shareholders and the share price.
Key Highlights of the Offering
- Offering Size and Structure: NeoGenomics is offering \$275 million in convertible senior notes, with an option for initial purchasers to buy up to an additional \$41.25 million within 13 days of issuance.
- Investor Eligibility: The notes are only available to qualified institutional buyers under Rule 144A of the Securities Act of 1933.
- Terms of the Notes:
- Senior, unsecured obligations of NeoGenomics.
- Interest is payable semi-annually in arrears.
- Maturity date is July 1, 2032, unless earlier converted, redeemed, or repurchased.
- Convertible into cash, shares of common stock, or a combination, at NeoGenomics’ election.
- Notes are redeemable (in whole or in part) for cash at NeoGenomics’ option on or after July 6, 2029, if the stock price equals or exceeds 130% of the conversion price for a specified period.
- Also redeemable if less than 15% of the original principal amount remains outstanding and certain conditions are met.
- Final interest rate, conversion rate, and other terms will be set at pricing.
Strategic Capped Call Transactions
- NeoGenomics intends to enter into capped call transactions with initial purchasers or financial institutions to reduce potential dilution upon note conversion and/or offset excess cash payments.
- Counterparties may purchase NeoGenomics shares and engage in derivative transactions, potentially influencing the share price during and after the offering.
- These transactions could increase (or reduce the size of any decrease in) the stock price or note value, affecting conversion dynamics and settlement amounts for noteholders.
Use of Proceeds: Debt Repurchase and Share Buyback
- A portion of the net proceeds will fund the capped call transactions.
- NeoGenomics plans to use remaining proceeds, along with cash on hand, to repurchase a portion of its existing 0.25% convertible senior notes due 2028 via privately negotiated transactions.
- The company also intends to repurchase up to \$25 million of its common stock from purchasers of the new notes, also via privately negotiated deals.
- The remainder of net proceeds may be used for general corporate purposes.
- Repurchases of notes and shares could result in higher share prices, potentially raising the initial conversion price for the new notes.
Potential Share Price Impact — What Investors Should Know
- The concurrent repurchase activities and hedging by holders of existing notes may drive significant buying in NeoGenomics’ common stock, leading to increased share prices around the time of the offering.
- These activities are price-sensitive and may affect the market value of both the shares and the new notes, especially during the pricing period.
- Hedged holders of existing notes may unwind positions and buy substantial amounts of stock, which could impact trading volumes and price volatility.
- The company cannot predict the magnitude of this market activity or its exact effect on share prices or note conversion terms.
Important Legal and Regulatory Notes
- The notes and any conversion shares will not be registered under the Securities Act or other securities laws and may not be offered or sold absent registration or an applicable exemption.
- This announcement does not constitute an offer to sell or buy the notes or repurchase existing notes or common stock in any jurisdiction where such actions are unlawful.
About NeoGenomics
NeoGenomics is a leading cancer diagnostics company specializing in cancer genetics testing and information services, serving a diverse clientele that includes oncologists, hospital systems, academic centers, and pharmaceutical firms. The company operates a network of accredited laboratories in the U.S. and the U.K.
Forward-Looking Statements & Risks
This release contains forward-looking statements about the proposed notes offering, the capped call transactions, repurchases, and other strategic actions. These statements are subject to risks including market acceptance, regulatory factors, and other uncertainties as detailed in the company’s SEC filings. Investors should not place undue reliance on these statements and are encouraged to review SEC risk disclosures.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The company’s actions described herein are subject to risks and uncertainties that could materially affect financial results and share prices.
